Improving patient convenience and substantially reducing dissociative effects of ketamine for the treatment of MDD and TRD

The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

The pharmacokinetic profile of this prolonged release formulation could significantly improve the tolerability and patient convenience, by minimizing dissociative effects compared with the currently applied intravenous and intranasal therapies.

TRD patients with insufficient response to standard antidepressants represent 30% of all patients suffering from MDD. In this group, our oral prolonged-release formulation of ketamine has shown good response rates.

HMNC Brain Health is planning to advance its investigational oral prolonged-release formulation of ketamine for the treatment of MDD with a pivotal clinical Phase 3 study in 2025.

If you'd like to learn more about KET01 and how we're working to make it available to patients, please visit our website at www.ketabon.health There you can find more information about this promising treatment option.